- Home
- KTF vs RIGL Comparison
KTF vs RIGL Comparison
Compare KTF & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTF
- RIGL
- Stock Information
- Founded
- KTF 1988
- RIGL 1996
- Country
- KTF United States
- RIGL United States
- Employees
- KTF N/A
- RIGL N/A
- Industry
- KTF Finance Companies
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- KTF Finance
- RIGL Health Care
- Exchange
- KTF Nasdaq
- RIGL Nasdaq
- Market Cap
- KTF 337.7M
- RIGL 335.5M
- IPO Year
- KTF N/A
- RIGL 2000
- Fundamental
- Price
- KTF $8.79
- RIGL $38.85
- Analyst Decision
- KTF
- RIGL Buy
- Analyst Count
- KTF 0
- RIGL 5
- Target Price
- KTF N/A
- RIGL $38.20
- AVG Volume (30 Days)
- KTF 103.3K
- RIGL 995.6K
- Earning Date
- KTF 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- KTF 3.54%
- RIGL N/A
- EPS Growth
- KTF N/A
- RIGL N/A
- EPS
- KTF 0.39
- RIGL 5.43
- Revenue
- KTF N/A
- RIGL $267,921,000.00
- Revenue This Year
- KTF N/A
- RIGL $59.93
- Revenue Next Year
- KTF N/A
- RIGL N/A
- P/E Ratio
- KTF $23.10
- RIGL $7.15
- Revenue Growth
- KTF N/A
- RIGL 105.62
- 52 Week Low
- KTF $7.40
- RIGL $12.66
- 52 Week High
- KTF $9.12
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- KTF 63.49
- RIGL 68.57
- Support Level
- KTF $8.63
- RIGL $39.00
- Resistance Level
- KTF $8.74
- RIGL $42.08
- Average True Range (ATR)
- KTF 0.06
- RIGL 2.32
- MACD
- KTF 0.02
- RIGL -0.37
- Stochastic Oscillator
- KTF 96.12
- RIGL 53.26
About KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.